ArticleDiabetes, obesity & metabolism2026
Discontinuation of SGLT2i After a Urogenital Infection: A Population-Based Matched Cohort Study of Patients With Type 2 Diabetes.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discontinuation of SGLT2i After a Urogenital Infection: A Population-Based Matched Cohort Study of Patients With Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsSodium-glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common. Guidelines do not generally recommend stopping treatment after a urinary tract infection (UTI) or genital tract infection (GTI). We investigated the impact of these infections on SGLT2i discontinuation. MATERIALS AND
methodsWe conducted a population-based matched cohort study of new SGLT2i users with Type 2 diabetes in Denmark during 2016-2021. All SGLT2i users with an incident UTI or GTI episode within the first year after treatment initiation were matched 1:3 to users without a UTI/GTI by sex, age, treatment duration and calendar year. Discontinuation was defined as not filling a new prescription within 60 days after previous medication supply ended.
resultsAmong 68 277 SGLT2i initiators, 5892 (8.6%) experienced UTI and 1389 (2%) experienced GTI during the following year. Among users with versus without UTI, discontinuation was 21.9% versus 14.3% on the date of the first expected SGLT2i refill (excess risk among users with UTI: 7.6% [95% CI 6.4%, 8.8%]), increasing to 39.5% versus 28.6% after 1 year. Among users with versus without GTI, discontinuation was 17.9% versus 15.6% (excess risk: 2.2% [95% CI -0.1%, 4.5%]) on the date of the first expected refill, rising to 43.6% versus 30.3% after 1 year.
conclusionsPatients with Type 2 diabetes who initiate SGLT2i and experience a UTI or GTI within the following year have an elevated frequency of subsequent SGLT2i discontinuation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.